Marker Therapeutics, Inc.

Monthly Archives: September 2015

TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer

…Trial will Utilize Folate Receptor Alpha Vaccine Licensed to TapImmune for Commercialization

JACKSONVILLE, Florida, September 15, 2015 /PRNewswire/ –

TapImmune, Inc. (TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280 patient Phase II Clinical Trial of Folate Receptor Alpha Vaccine in patients with Triple Negative Breast Cancer.

Read More